Anti-Galectin-9 antibodies and uses thereof
First Claim
Patent Images
1. An isolated antibody, which binds human galactin-9, wherein the antibody comprises a heavy chain complementarity determining region 1 (CDR1) set forth as SEQ ID NO:
- 361, a heavy chain complementary determining region 2 (CDR2) set forth as SEQ ID NO;
388, and a heavy chain complementary determining region 3 (CDR3) set forth as SEQ ID NO;
406 and/or comprises a light chain complementarity determining region 1 (CDR1) set forth as SEQ ID NO;
328, a light chain complementary determining region 2 (CDR2) set forth as SEQ ID NO;
329, and a light chain complementary determining region 3 (CDR3) set forth as SEQ ID NO;
352.
5 Assignments
0 Petitions
Accused Products
Abstract
Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.
-
Citations
30 Claims
-
1. An isolated antibody, which binds human galactin-9, wherein the antibody comprises a heavy chain complementarity determining region 1 (CDR1) set forth as SEQ ID NO:
- 361, a heavy chain complementary determining region 2 (CDR2) set forth as SEQ ID NO;
388, and a heavy chain complementary determining region 3 (CDR3) set forth as SEQ ID NO;
406 and/or comprises a light chain complementarity determining region 1 (CDR1) set forth as SEQ ID NO;
328, a light chain complementary determining region 2 (CDR2) set forth as SEQ ID NO;
329, and a light chain complementary determining region 3 (CDR3) set forth as SEQ ID NO;
352. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)
- 361, a heavy chain complementary determining region 2 (CDR2) set forth as SEQ ID NO;
Specification